FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200573629> ?p ?o ?g. }

• W4200573629 abstract "ABSTRACT Background Thrombosis of the lung micro-vasculature is a characteristic of COVID-19 disease, which is observed in large excess compared to other forms of acute respiratory distress syndrome and thus suggests a trigger for thrombosis endogenous to the lung. Our recent work has shown that the SARS-CoV-2 Spike protein activates the cellular TMEM16F chloride channel and scramblase. Through a screening on >3,000 FDA/EMA approved drugs, we identified Niclosamide and Clofazimine as the most effective molecules at inhibiting this activity. As TMEM16F plays an important role in the stimulation of the pro-coagulant activity of platelets, and considering that platelet abnormalities are common in COVID-19 patients, we investigated whether Spike directly affects platelet activation and pro-thrombotic function and tested the effect of Niclosamide and Clofazimine on these processes. Methods We produced SARS-CoV-2 Spike or VSV-G protein-pseudotyped virions, or generated cells expressing Spike on their plasma membrane, and tested their effects on platelet adhesion (fluorescence), aggregation (absorbance), exposure of phosphatidylserine (flow cytometry for annexin V binding), calcium flux (flow cytometry for fluo-4 AM), and clot formation and retraction. These experiments were also conducted in the presence of the TMEM16F activity inhibitors Niclosamide and Clofazimine. Results Here we show that exposure to SARS-CoV-2 Spike promotes platelet activation, adhesion and spreading, both when present on the envelope of virions or upon expression on the plasma membrane of cells. Spike was effective both as a sole agonist or by enhancing the effect of known platelet activators, such as collagen and collagen-related peptide. In particular, Spike exerted a noticeable effect on the procoagulant phenotype of platelets, by enhancing calcium flux, phosphatidylserine externalisation, and thrombin generation. Eventually, this resulted in a striking increase in thrombin-induced clot formation and retraction. Both Niclosamide and Clofazimine almost abolished this Spike-induced pro-coagulant response. Conclusions Together, these findings provide a pathogenic mechanism to explain thrombosis associated to COVID-19 lung disease, by which Spike present in SARS-CoV-2 virions or exposed on the surface of infected cells, leads to local platelet stimulation and subsequent activation of the coagulation cascade. As platelet TMEM16F is central in this process, these findings reinforce the rationale of repurposing drugs targeting this protein, such as Niclosamide, for COVID-19 therapy." @default.
• W4200573629 created "2021-12-31" @default.
• W4200573629 creator A5000828816 @default.
• W4200573629 creator A5006089663 @default.
• W4200573629 creator A5013333915 @default.
• W4200573629 creator A5016365022 @default.
• W4200573629 creator A5022450686 @default.
• W4200573629 creator A5038230299 @default.
• W4200573629 creator A5044812537 @default.
• W4200573629 creator A5046467955 @default.
• W4200573629 creator A5055712810 @default.
• W4200573629 creator A5056483000 @default.
• W4200573629 creator A5074876248 @default.
• W4200573629 creator A5079328931 @default.
• W4200573629 creator A5079810176 @default.
• W4200573629 date "2021-12-15" @default.
• W4200573629 modified "2023-10-16" @default.
• W4200573629 title "SARS-CoV-2 Spike protein activates TMEM16F-mediated platelet pro-coagulant activity" @default.
• W4200573629 cites W1515820929 @default.
• W4200573629 cites W1987365088 @default.
• W4200573629 cites W2000178601 @default.
• W4200573629 cites W2002124320 @default.
• W4200573629 cites W2064076043 @default.
• W4200573629 cites W2064369146 @default.
• W4200573629 cites W2101506295 @default.
• W4200573629 cites W2131727825 @default.
• W4200573629 cites W2140674451 @default.
• W4200573629 cites W2167629505 @default.
• W4200573629 cites W2519183709 @default.
• W4200573629 cites W2587090657 @default.
• W4200573629 cites W2800567075 @default.
• W4200573629 cites W2913305156 @default.
• W4200573629 cites W3001118548 @default.
• W4200573629 cites W3012290165 @default.
• W4200573629 cites W3014003872 @default.
• W4200573629 cites W3014713654 @default.
• W4200573629 cites W3015200765 @default.
• W4200573629 cites W3015886046 @default.
• W4200573629 cites W3016393661 @default.
• W4200573629 cites W3016489853 @default.
• W4200573629 cites W3016508437 @default.
• W4200573629 cites W3017125154 @default.
• W4200573629 cites W3017326650 @default.
• W4200573629 cites W3018507926 @default.
• W4200573629 cites W3020482683 @default.
• W4200573629 cites W3020655115 @default.
• W4200573629 cites W3021056079 @default.
• W4200573629 cites W3022187628 @default.
• W4200573629 cites W3024128175 @default.
• W4200573629 cites W3027918021 @default.
• W4200573629 cites W3036681929 @default.
• W4200573629 cites W3039983944 @default.
• W4200573629 cites W3040934200 @default.
• W4200573629 cites W3082011975 @default.
• W4200573629 cites W3085715897 @default.
• W4200573629 cites W3094684299 @default.
• W4200573629 cites W3095588278 @default.
• W4200573629 cites W3111220432 @default.
• W4200573629 cites W3118978773 @default.
• W4200573629 cites W3119177573 @default.
• W4200573629 cites W3126061642 @default.
• W4200573629 cites W3128550076 @default.
• W4200573629 cites W3129390470 @default.
• W4200573629 cites W3140915421 @default.
• W4200573629 cites W3152312420 @default.
• W4200573629 cites W3159729619 @default.
• W4200573629 cites W3194027058 @default.
• W4200573629 cites W3196420897 @default.
• W4200573629 cites W3196483729 @default.
• W4200573629 cites W4205129832 @default.
• W4200573629 doi "https://doi.org/10.1101/2021.12.14.472668" @default.
• W4200573629 hasPublicationYear "2021" @default.
• W4200573629 type Work @default.
• W4200573629 citedByCount "1" @default.
• W4200573629 countsByYear W42005736292022 @default.
• W4200573629 crossrefType "posted-content" @default.
• W4200573629 hasAuthorship W4200573629A5000828816 @default.
• W4200573629 hasAuthorship W4200573629A5006089663 @default.
• W4200573629 hasAuthorship W4200573629A5013333915 @default.
• W4200573629 hasAuthorship W4200573629A5016365022 @default.
• W4200573629 hasAuthorship W4200573629A5022450686 @default.
• W4200573629 hasAuthorship W4200573629A5038230299 @default.
• W4200573629 hasAuthorship W4200573629A5044812537 @default.
• W4200573629 hasAuthorship W4200573629A5046467955 @default.
• W4200573629 hasAuthorship W4200573629A5055712810 @default.
• W4200573629 hasAuthorship W4200573629A5056483000 @default.
• W4200573629 hasAuthorship W4200573629A5074876248 @default.
• W4200573629 hasAuthorship W4200573629A5079328931 @default.
• W4200573629 hasAuthorship W4200573629A5079810176 @default.
• W4200573629 hasBestOaLocation W42005736291 @default.
• W4200573629 hasConcept C12554922 @default.
• W4200573629 hasConcept C153911025 @default.
• W4200573629 hasConcept C185592680 @default.
• W4200573629 hasConcept C188810444 @default.
• W4200573629 hasConcept C202751555 @default.
• W4200573629 hasConcept C203014093 @default.
• W4200573629 hasConcept C2778914503 @default.
• W4200573629 hasConcept C2778918659 @default.
• W4200573629 hasConcept C2779637612 @default.
• W4200573629 hasConcept C2780076745 @default.

• next